Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer (Q38242086)

31 August 2017

Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer (English)

1 reference

31 August 2017

2

1 reference

31 August 2017

Hui Jun Lim

1

1 reference

PubMed ID

25146530

31 August 2017

Jia-Lin Yang

series ordinal

3

1 reference

31 August 2017

22 August 2014

1 reference

Journal of Cancer Research and Clinical Oncology

31 August 2017

1 reference

31 August 2017

141

1 reference

31 August 2017

4

1 reference

31 August 2017

671-689

1 reference

https://scigraph.springernature.com/pub.10.1007/s00432-014-1803-3

31 August 2017

0 references

cites work

Combinatorial drug therapy for cancer in the post-genomic era.

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Involvement of miR-21 in resistance to daunorubicin by regulating PTEN expression in the leukaemia K562 cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Discovery of molecular subtypes in leiomyosarcoma through integrative molecular profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

The genomic complexity of primary human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

AKT1(E17K) in human solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Phase I study of temsirolimus in combination with EKB-569 in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Phase I trial of the combination of the Akt inhibitor nelfinavir and chemoradiation for locally advanced rectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Phase I dose-escalation study of 5-day intermittent oral lapatinib therapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

RTOG 0913: a phase 1 study of daily everolimus (RAD001) in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Phase 1 and pharmacodynamic trial of everolimus in combination with cetuximab in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

The PI3K pathway as drug target in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

PTEN is a potent suppressor of small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Concurrent chemoradiotherapy versus induction chemotherapy followed by chemoradiotherapy (sequential approach) in the management of head and neck cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Phase Ib study of tivozanib (AV-951) in combination with temsirolimus in patients with renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Phase II trial of temsirolimus in patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Perifosine treatment in chronic lymphocytic leukemia: results of a phase II clinical trial and in vitro studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

PI3K and cancer: lessons, challenges and opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

PIK3CA gene mutations in pediatric and adult glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Phase I clinical trial of lenalidomide in combination with temsirolimus in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

miR-17 inhibitor suppressed osteosarcoma tumor growth and metastasis via increasing PTEN expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

New insights in sarcoma oncogenesis: a comprehensive analysis of a large series of 160 soft tissue sarcomas with complex genomics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Targeting EGFR and PI3K pathways in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Molecular subtypes of glioblastoma are relevant to lower grade glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Exploiting the PI3K/AKT pathway for cancer drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

A reinvestigation of somatic hypermethylation at the PTEN CpG island in cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

PTEN function: the long and the short of it.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Putative chemopreventive molecules can increase Nrf2-regulated cell defense in some human cancer cell lines, resulting in resistance to common cytotoxic therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Inhibitors of phosphatidylinositol-3-kinase in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Phase I safety and pharmacokinetic study of the PI3K/mTOR inhibitor SAR245409 (XL765) in combination with erlotinib in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Alternative dosing of dual PI3K and MEK inhibition in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

PIK3CA alterations in primary (de novo) and secondary glioblastomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

A phase II study evaluating the toxicity and efficacy of single-agent temsirolimus in chemotherapy-naïve castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

MiR-124 suppresses cell proliferation in hepatocellular carcinoma by targeting PIK3CA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Frequent mutation of the PIK3CA gene in ovarian and breast cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Loss of heterozygosity on 10q23.3 and mutation of tumor suppressor gene PTEN in gastric cancer and precancerous lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

A phase I study of ridaforolimus in adult Chinese patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

High-dose accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy/fraction) with concurrent vinorelbine and carboplatin chemotherapy in locally advanced non-small-cell lung cancer: a feasibility study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Complexity in the signaling network: insights from the use of targeted inhibitors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

The search continues: looking for predictive biomarkers for response to mammalian target of rapamycin inhibition in endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Frequent promoter hypermethylation of BRCA2, CDH13, MSH6, PAX5, PAX6 and WT1 in ductal carcinoma in situ and invasive breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Frequency of germline PTEN mutations in differentiated thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Phase II study of everolimus in patients with metastatic colorectal adenocarcinoma previously treated with bevacizumab-, fluoropyrimidine-, oxaliplatin-, and irinotecan-based regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Second malignant neoplasms in patients with Cowden syndrome with underlying germline PTEN mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

PIK3CA mutation and amplification in human lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Akt inhibitors in clinical development for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Role of PTEN promoter methylation in tamoxifen-resistant breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Alterations of EGFR, p53 and PTEN that mimic changes found in basal-like breast cancer promote transformation of human mammary epithelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

A phase I study of temsirolimus and bryostatin-1 in patients with metastatic renal cell carcinoma and soft tissue sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

A mosaic PTEN mutation causing Cowden syndrome identified by deep sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Overall survival benefits for combining targeted therapy as second-line treatment for advanced non-small-cell-lung cancer: a meta-analysis of published data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

High frequency of mutations of the PIK3CA gene in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

The biology and clinical relevance of the PTEN tumor suppressor pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

MicroRNA-128 promotes proliferation in osteosarcoma cells by downregulating PTEN.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

PTEN is a protein tyrosine phosphatase for IRS1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

A phase-1b study of everolimus plus paclitaxel in patients with small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

A dose-finding study of temsirolimus and liposomal doxorubicin for patients with recurrent and refractory bone and soft tissue sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Four microRNAs promote prostate cell proliferation with regulation of PTEN and its downstream signals in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Toward a NOTCH1/FBXW7/RAS/PTEN-based oncogenetic risk classification of adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

MDM2, MDMX and p53 in oncogenesis and cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Multimodal biomarker investigation on efficacy and mechanism of action for the mammalian target of rapamycin inhibitor, temsirolimus, in a preclinical mammary carcinoma OncoMouse model: a translational medicine study in support for early clinical de

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Temsirolimus enhances the efficacy of cetuximab in colon cancer through a CIP2A-dependent mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

MicroRNA-375 inhibits colorectal cancer growth by targeting PIK3CA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

A phase I study of temsirolimus and thoracic radiation in non--small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Phase I study of everolimus and mitomycin C for patients with metastatic esophagogastric adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Cutaneous T cell lymphoma: update on treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Multicenter phase II study of tivozanib (AV-951) and everolimus (RAD001) for patients with refractory, metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Targeting the PI3K signaling pathway in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

MicroRNA-32 (miR-32) regulates phosphatase and tensin homologue (PTEN) expression and promotes growth, migration, and invasion in colorectal carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Combined PTEN Mutation and Protein Expression Associate with Overall and Disease-Free Survival of Glioblastoma Patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

PIK3CA mutations and copy number gains in human lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

PTEN mutation spectrum in breast cancers and breast hyperplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Analysis of PTEN methylation patterns in soft tissue sarcomas by MassARRAY spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Genomic Deletion of PTEN Is Associated with Tumor Progression and Early PSA Recurrence in ERG Fusion-Positive and Fusion-Negative Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245409 (XL765), a Novel, Orally Administered PI3K/mTOR Inhibitor in Patients with Advanced Solid Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

PTEN expression in non–small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1803-3

The functions and regulation of the PTEN tumour suppressor

21 January 2018

1 reference

12 December 2020

Combination versus sequential single agent chemotherapy for metastatic breast cancer

1 reference

12 December 2020

High prevalence and mutual exclusivity of genetic alterations in the phosphatidylinositol-3-kinase/akt pathway in thyroid tumors

1 reference

12 December 2020

Comparative analyses of individual and multiple alterations of p53, PTEN and p16 in non-small cell lung carcinoma, glioma and breast carcinoma samples.

1 reference

12 December 2020

mTOR inhibitor AZD8055 inhibits proliferation and induces apoptosis in laryngeal carcinoma

1 reference

12 December 2020

Effectiveness of targeted therapy as monotherapy or combined therapy in patients with relapsed or refractory multiple myeloma: a systematic review and meta-analysis

1 reference

12 December 2020

PIK3CA mutations are mutually exclusive with PTEN loss in diffuse large B-cell lymphoma

1 reference

12 December 2020

Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer

1 reference

12 December 2020

Randomized placebo-controlled phase II trial of perifosine plus capecitabine as second- or third-line therapy in patients with metastatic colorectal cancer

1 reference

12 December 2020

Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors

1 reference

12 December 2020

Roles of PTEN (Phosphatase and Tensin Homolog) in gastric cancer development and progression

1 reference

12 December 2020

A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma

1 reference

12 December 2020

Efficacy of everolimus in patients with advanced renal cell carcinoma refractory or intolerant to VEGFR-TKIs and safety compared with prior VEGFR-TKI treatment

1 reference

12 December 2020

PTEN promoter is methylated in a proportion of invasive breast cancers

1 reference

12 December 2020

Phase I and pharmacokinetic study of combined treatment with perifosine and radiation in patients with advanced solid tumours

1 reference

12 December 2020

Epigenetic and genetic alterations of PTEN in hepatocellular carcinoma

1 reference

12 December 2020

Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer

1 reference

12 December 2020

Mutational analysis of p53 and PTEN in soft tissue sarcoma

1 reference

12 December 2020

PTEN mutation, loss of heterozygosity, promoter methylation and expression in colorectal carcinoma: two hits on the gene?

1 reference

12 December 2020

A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors

1 reference

12 December 2020

Tumor suppressor PTEN in breast cancer: heterozygosity, mutations and protein expression.

1 reference

12 December 2020

Phase Ib study of Buparlisib plus Trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on Trastuzumab-based therapy

1 reference

12 December 2020

10.1007/S00432-014-1803-3

Identifiers

DOI

1 reference

31 August 2017

1 reference

PubMed ID

25146530